Tenax Therapeutics Inc. (TENX)
NASDAQ: TENX
· Real-Time Price · USD
6.81
0.31 (4.77%)
At close: Sep 25, 2025, 3:59 PM
6.81
0.00%
After-hours: Sep 25, 2025, 05:14 PM EDT
4.77% (1D)
| Bid | 6.78 |
| Market Cap | 31.07M |
| Revenue (ttm) | 2K |
| Net Income (ttm) | -31.48M |
| EPS (ttm) | 2.94 |
| PE Ratio (ttm) | 2.32 |
| Forward PE | -2.62 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 6.95 |
| Volume | 551,161 |
| Avg. Volume (20D) | 36,488 |
| Open | 6.50 |
| Previous Close | 6.50 |
| Day's Range | 6.50 - 7.13 |
| 52-Week Range | 3.25 - 7.89 |
| Beta | 1.44 |
| Ex-Dividend Date | n/a |
About TENX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol TENX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for TENX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts6 months ago
+3.15%
Tenax Therapeutics shares are trading higher after...
Unlock content with
Pro Subscription
11 months ago
+10.65%
Tenax Therapeutics shares are trading higher after Leerink Partners initiated coverage on the stock with an Outperform rating and announced a price target of $16.
5 months ago · seekingalpha.com
Tenax: Phase 3 Heart Failure Program Continues With 2 Key CatalystsTenax Therapeutics is advancing levosimendan in two phase 3 studies for PH-HFpEF, with LEVEL-2 starting in 2025 and topline data from LEVEL expected mid-2026. Levosimendan could be the first disease-m...